Kiora Current Valuation

KPRX
 Stock
  

USD 3.73  0.02  0.54%   

Kiora Pharmaceuticals fundamentals help investors to digest information that contributes to Kiora Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kiora Stock. The fundamental analysis module provides a way to measure Kiora Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kiora Pharmaceuticals stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Kiora Current Valuation Analysis

Kiora Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value 
 = 
Market Cap + Debt 
-  
Cash 
More About Current Valuation | All Equity Analysis

Current Kiora Pharmaceuticals Current Valuation

    
  3.49 M  
Most of Kiora Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kiora Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Compare to competition

In accordance with the recently published financial statements, Kiora Pharmaceuticals has a Current Valuation of 3.49 M. This is 99.98% lower than that of the Healthcare sector and 99.92% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.98% higher than that of the company.

Kiora Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kiora Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kiora Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiora Pharmaceuticals by comparing valuation metrics of similar companies.
Kiora Pharmaceuticals is currently under evaluation in current valuation category among related companies.

Kiora Fundamentals

About Kiora Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kiora Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiora Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiora Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kiora Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kiora Pharmaceuticals' short interest history, or implied volatility extrapolated from Kiora Pharmaceuticals options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kiora Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Kiora Pharmaceuticals Piotroski F Score and Kiora Pharmaceuticals Altman Z Score analysis. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for analysis

When running Kiora Pharmaceuticals price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.3 M
Return On Assets
(0.29) 
Return On Equity
(1.24) 
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Kiora Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.